J&J and Bayer’s Xarelto wins where Pfizer drug lost – FierceBiotech



ThirdAge
J&J and Bayer's Xarelto wins where Pfizer drug lost
FierceBiotech
The blood-thinner Xarelto has added some upbeat Phase III data to its resume. Bayer ($ BAYN), which is co-developing the drug with Johnson & Johnson ($ JNJ), said the drug met its primary efficacy endpoint in sufferers of acute coronary syndrome.
Bayer, J&J's Xarelto Helped Acute Coronary Syndrome PatientsBusinessWeek
Xarelto Found to Help Angina and Heart Attack PatientsThirdAge
Bayer, J&J Blood Thinner Rivaroxaban Met Primary Goal In Phase III TrialRTT News
Pharma Times -Bloomberg
all 13 news articles »

Pharmaceuticals – Google News